Literature DB >> 9409788

Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B.

G Coia1, A Ayres, G G Lilley, P J Hudson, R A Irving.   

Abstract

A mutation strategy which utilises phage display technology and the Escherichia coli mutator strains, mutD5-FIT and XL1-RED, was applied to a Hepatitis B (HepB) specific single-chain Fv (scFv) to incorporate random mutations throughout the gene. Messenger RNA from a hybridoma producing antibodies against HepB was isolated, reverse transcribed and used as template for the production of scFv. Following production of the scFv protein using an E. coli expression vector (pGC), the scFv gene was recloned into a phage display vector (pHFA). This gene construct was introduced into E. coli mutator cells and the transformed cells were used as an inoculum for liquid cultures. After five cycles of growth at 37 degrees C, each followed by dilution and re-inoculation of fresh media, recombinant phage were recovered. Nucleotide sequence analysis of the scFv gene in phage selected on HBsAg-coated magnetic beads identified amino acid substitutions which produced an increase of greater than 10-fold in apparent production levels. Competitive ELISA studies showed that the selected scFv mutants appeared to have similar affinity to HBsAg as the parent scFv. The apparent increase in production was not the result of improved surface characteristics of regions uniquely exposed in scFvs, as the sites did not correlate with the variable/constant interface of the scFv variable region normally masked in Fabs or IgGs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409788     DOI: 10.1016/s0378-1119(97)00452-6

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype.

Authors:  Victor A Streltsov; Jennifer A Carmichael; Stewart D Nuttall
Journal:  Protein Sci       Date:  2005-09-30       Impact factor: 6.725

2.  The rescue by phage display of human Fabs to gp120 HIV-1 glycoprotein using EBV transformed lymphocytes.

Authors:  E Kempf; E Weiss; P Klein; A Glacet; S Spratt; D Bourel; G Orfanoudakis
Journal:  Mol Biotechnol       Date:  2001-02       Impact factor: 2.695

3.  In vivo elimination of parental clones in general and site-directed mutagenesis.

Authors:  Erika G Holland; Felicity E Acca; Kristina M Belanger; Mary E Bylo; Brian K Kay; Michael P Weiner; Margaret M Kiss
Journal:  J Immunol Methods       Date:  2014-12-15       Impact factor: 2.303

4.  Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains.

Authors:  Fiona Wightman; Tomos Walters; Anna Ayres; Scott Bowden; Angeline Bartholomeusz; Daryl Lau; Stephen Locarnini; Sharon R Lewin
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 5.  Mutant library construction in directed molecular evolution: casting a wider net.

Authors:  Tian-Wen Wang; Hu Zhu; Xing-Yuan Ma; Ting Zhang; Yu-Shu Ma; Dong-Zhi Wei
Journal:  Mol Biotechnol       Date:  2006-09       Impact factor: 2.860

6.  OverFlap PCR: A reliable approach for generating plasmid DNA libraries containing random sequences without a template bias.

Authors:  Artis Linars; Ivars Silamikelis; Dita Gudra; Ance Roga; Davids Fridmanis
Journal:  PLoS One       Date:  2022-08-08       Impact factor: 3.752

7.  Protein engineering with biosynthesized libraries from Bordetella bronchiseptica bacteriophage.

Authors:  Tom Z Yuan; Cathie M Overstreet; Issa S Moody; Gregory A Weiss
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

8.  Improvement of a recombinant antibody-based serological assay for foot-and-mouth disease virus.

Authors:  Janine D Muller; Michelle Wilkins; Adam J Foord; Olan Dolezal; Meng Yu; Hans G Heine; Lin-Fa Wang
Journal:  J Immunol Methods       Date:  2009-11-11       Impact factor: 2.303

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.